Memo Therapeutics’ Phase 2 data show sustained BK polyomavirus reductions and kidney-biopsy improvement, but a missed primary endpoint leaves its pivotal trial carrying the decisive burden.
Evategrel could offer rapid and consistent platelet inhibition through oral and intravenous formulations, but early volunteer data cannot establish cardiovascular protection or safety.
The first United States-approved oral carbapenem could replace intravenous therapy for selected complicated urinary tract infections, but stewardship, four-times-daily dosing and resistance risks will constrain its use.
The Food and Drug Administration will accept uniQure’s three-year AMT-130 data as the primary basis for an accelerated approval filing, but external controls, irreversible brain delivery and confirmatory evidence remain decisive risks.
Replicate Bioscience is extending its low-dose self-replicating RNA platform into tuberculosis, but immunological complexity, late-stage competition and global affordability create a demanding development path.
Denali Therapeutics is converting AVLAYAH’s regulatory reward into non-dilutive capital for its blood-brain barrier pipeline, but clinical and commercial risks remain.
Updated 9MW2821 data support Nectin-4 as a target in cervical cancer, but Mabwell must prove that early response and survival signals outperform established ADC and immunotherapy options.
Early ixotatug vedotin and bevacizumab data suggest activity in Claudin 6-positive ovarian cancer, but the small uncontrolled study cannot yet separate ADC efficacy from combination effects.
KIT2014 cleared its first human safety study with no measurable systemic exposure, but Kither Biotech must now prove that its peptide can improve lung function and inflammation in patients.
The ENERGY trial strengthens the regulatory case for nipocalimab in warm autoimmune hemolytic anemia, but modest response rates and long-term IgG suppression remain important questions.